Related Experiment Video
Updated: May 2, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.2K
Beyond pathology: APP, brain development and Alzheimer's disease
Alessia Soldano1, Bassem A Hassan1
1VIB Center for the Biology of Disease, VIB, 3000 Leuven, Belgium; Center for Human Genetics, University of Leuven School of Medicine, 3000 Leuven, Belgium.
Current Opinion in Neurobiology
|March 18, 2014
Summary
Alzheimer's disease research is shifting focus from Aβ peptides to the amyloid precursor protein (APP). Understanding APP's physiological role is crucial for unraveling Alzheimer's disease (AD) pathology and brain wiring mechanisms.
Area of Science:
- Neuroscience
- Molecular Biology
- Dementia Research
Background:
- Alzheimer's disease (AD) is the leading cause of dementia in older adults.
- Historically, AD research prioritized the amyloid-beta (Aβ) peptide.
- Emerging evidence highlights the significance of the amyloid precursor protein (APP) in AD.
Purpose of the Study:
- To review the physiological functions of APP.
- To explore the molecular mechanisms underlying APP's role in brain health.
- To shift focus towards APP's importance in understanding AD pathology.
Main Methods:
- Literature review of current research on APP.
- Analysis of molecular mechanisms related to APP function.
- Synthesis of evidence linking APP to brain wiring and AD.
Main Results:
- APP plays a critical role in ensuring the accuracy and robustness of neural connections (brain wiring).
- APP's functions are central to maintaining proper brain architecture.
- Understanding APP's molecular pathways is key to understanding AD.
Conclusions:
- The physiological role of APP is increasingly recognized as vital for brain function.
- APP's involvement in brain wiring mechanisms offers new perspectives on Alzheimer's disease.
- Further investigation into APP's molecular functions is warranted for AD therapeutic strategies.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28